Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.525 +0.145 (+1.96%)

Streaming Delayed Price Updated: 11:10 AM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX

March 26, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Reversal Alert: VTIX, MARA, IBRX, BATL, NDRA, EEIQ Gain Momentum as Multi-Sector Catalysts Build

March 26, 2026

Via AB Newswire

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Via TheNewswire.com

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

March 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Via TheNewswire.com

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

March 24, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Stocks Under $10: IBRX, VTIX, NDRA, SMX – 2026 Watch Now!

March 19, 2026

Via AB Newswire

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

February 27, 2026

From ImmunityBio

Via Business Wire

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

February 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

February 19, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

February 18, 2026

From ImmunityBio, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

February 17, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)

February 10, 2026

Via AB Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!

January 25, 2026

Via AB Newswire

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.